Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D02FWA
|
|||
| Drug Name |
Naphthalene derivative 1
|
|||
| Synonyms |
PMID28454500-Compound-62
Click to Show/Hide
|
|||
| Drug Type |
Small molecular drug
|
|||
| Company |
RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY THE BROAD INSTITUTE, INC
|
|||
| Structure |
 |
Download2D MOL |
||
| Formula |
C25H24F3NO6S
|
|||
| Canonical SMILES |
CC1=CC(=C(C=C1)S(=O)(=O)NC2=CC(=C(C3=CC=CC=C32)O)C(C(=O)C(F)(F)F)C(=O)OC(C)C)C
|
|||
| InChI |
1S/C25H24F3NO6S/c1-13(2)35-24(32)21(23(31)25(26,27)28)18-12-19(16-7-5-6-8-17(16)22(18)30)29-36(33,34)20-10-9-14(3)11-15(20)4/h5-13,21,29-30H,1-4H3
|
|||
| InChIKey |
PCUXRYBEDDOJPT-UHFFFAOYSA-N
|
|||
| PubChem Compound ID | ||||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Keap1-Nrf2[dual DLG and ETGE] PPI (KEAP1-Nrf2 DLG and ETGE) | Target Info | Modulator | [1] |
| Nuclear factor erythroid 2-related factor 2 (Nrf2) | Target Info | Inhibitor | [1] | |
| Target's Patent Info | Keap1-Nrf2[dual DLG and ETGE] PPI (KEAP1-Nrf2 DLG and ETGE) | Target's Patent Info | [1] | |
| Nuclear factor erythroid 2-related factor 2 (Nrf2) | Target's Patent Info | [1] | ||
| KEGG Pathway | Protein processing in endoplasmic reticulum | |||
| NetPath Pathway | IL5 Signaling Pathway | |||
| WikiPathways | Oxidative Stress | |||
| Transcriptional activation by NRF2 | ||||
| NRF2 pathway | ||||
| Nuclear Receptors Meta-Pathway | ||||
| Aryl Hydrocarbon Receptor Pathway | ||||
| Mesodermal Commitment Pathway | ||||
| Aryl Hydrocarbon Receptor | ||||
| Quercetin and Nf-kB/ AP-1 Induced Cell Apoptosis | ||||
| Arylhydrocarbon receptor (AhR) signaling pathway | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Recent progress in the development of small molecule Nrf2 modulators: a patent review (2012-2016).Expert Opin Ther Pat. 2017 Jul;27(7):763-785. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.